Phesgo and Tecentriq Performance and Approvals
Tecentriq: Solid growth across all regions
First PD-(L)1 with pivotal SC results filed and PDUFA set for September 15th
CHFM
1,100
1,000
YoY CER growth
Q1 update
•
•
Roche
Ph III (IMbrave050) results in adjuvant HCC presented at AACR;
RFS primary endpoint met but OS immature
⚫ Ph III (IMpassion030) in adjuvant TNBC to be discontinued
Lung franchise (NSCLC, SCLC)
•
EU: Strong adjuvant NSCLC launch
• US: Growth in SCLC and adjuvant NSCLC
+15%
900
+8%
+26%
800
700
+99%
600
500
400
300
•
US/EU/Japan: Further growth in 1L HCC
200
100
Outlook 2023
0
⚫ Ph III (IMvoke010) results in adjuvant SCCHN expected in H2
Q1 20
Q1 21
Q122
Q1 23
•
US
Europe
International
Japan
Ph III (SKYSCRAPER-01) Tecentriq + tiragolumab in 1L NSCLC to
continue to final analysis, expected in Q3
Gl franchise (HCC)
CER=Constant Exchange Rates; SC=subcutaneous; NSCLC-non-small cell lung cancer; HCC-hepatocellular cancer; SCLC-small cell lung cancer; TNBC-triple-negative breast cancer; SCCHN-squamous cell carcinoma of
head and neck; PDUFA-prescription drug user fee act; RFS-recurrence free survival; OS-overall survival
23View entire presentation